Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120

RPH-120 is a novel fully human anti-PD-L1 IgG1 monoclonal antibody with specifically designed Asn300Ala mutation in Fc fragment. Surface plasmon resonance assay showed that affinity of the RPH-120 to the dimeric form of human PD-L1-Fc fusion protein was much higher than affinity to the monomeric His...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulikov, Andrey, Shipaeva, Elena, Dmitrieva, Anastasia, Batrak, Vera, Shipunov, Georgy, Guy, Colin, Smith, Jill, Zhang, Ran, Zhang, Michael, Duan, Jeff, Chestukhin, Anton, Barbashov, Sergei, Samsonov, Mikhail, Lavrovsky, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386121/
https://www.ncbi.nlm.nih.gov/pubmed/34456733
http://dx.doi.org/10.3389/fphar.2021.723038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386121/
https://www.ncbi.nlm.nih.gov/pubmed/34456733
http://dx.doi.org/10.3389/fphar.2021.723038

Ejemplares similares